Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT03906058Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Disease Control Rate at 30 months. Started Apr 2019; status: completed.
02
Drugs
anlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03906058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03906058.